Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a small update to the page’s versioning. This change does not alter any study details, eligibility criteria, or other user-visible content.SummaryDifference0.0%

- Check12 days agoChange DetectedA new line '2016 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, signaling an NIH grant/contract reference associated with the trial. This addition expands the funding/administrative attribution attached to the study record.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page's revision label was updated from v3.6.4 to v3.6.5, signaling a new release of the documentation. This likely reflects small corrections or minor updates since the previous version.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating a small maintenance update to the page rather than a content change.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision tag on the page was updated to Revision: v3.6.3, replacing the previous v3.6.0. This marks a new version of the page content without substantive changes to the trial details.SummaryDifference0.0%

- Check83 days agoChange DetectedRecruitment status was updated to 'No longer looking for participants', indicating enrollment is closed. The page also adds new help sections ('How to Read a Study Record', 'Common Questions', 'How to Join a Study') and updates the revision to v3.6.0, along with changing the label from 'Intervention / Treatment' to 'Intervention/Treatment'.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.